Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-Current Deffered Revenue (2016 - 2025)

Regenxbio has reported Non-Current Deffered Revenue over the past 8 years, most recently at $18.9 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $18.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $18.9 million (changed N/A YoY), and the annual figure for FY2025 was $18.9 million, changed.
  • Non-Current Deffered Revenue for Q4 2025 was $18.9 million at Regenxbio, down from $21.2 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for RGNX hit a ceiling of $26.3 million in Q1 2025 and a floor of $3.5 million in Q3 2021.